Home » Stocks » PSTV

Plus Therapeutics, Inc. (PSTV)

Stock Price: $2.17 USD -0.09 (-3.98%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $2.26 +0.09 (4.15%) May 7, 7:19 PM
Market Cap 45.80M
Revenue (ttm) 185,000
Net Income (ttm) -9.87M
Shares Out 8.27M
EPS (ttm) -30.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $2.17
Previous Close $2.26
Change ($) -0.09
Change (%) -3.98%
Day's Open 2.26
Day's Range 2.13 - 2.35
Day's Volume 1,208,919
52-Week Range 1.51 - 5.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

– Agreements are a major step for ongoing clinical trials and future commercial drug supply – Agreements are a major step for ongoing clinical trials and future commercial drug supply

3 days ago - GlobeNewsWire

Management to host conference call today at 5:00 pm ET Management to host conference call today at 5:00 pm ET

2 weeks ago - GlobeNewsWire

AUSTIN, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies ...

4 weeks ago - GlobeNewsWire

Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets Agreement covers intermediate drug product for RNL™, a radiotherapy in development for ...

1 month ago - GlobeNewsWire

AUSTIN, Texas, March 03, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and diffic...

2 months ago - GlobeNewsWire

– Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 –

2 months ago - GlobeNewsWire

AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies f...

2 months ago - GlobeNewsWire

AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for...

2 months ago - GlobeNewsWire

AUSTIN, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today announced ...

4 months ago - GlobeNewsWire

AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- P lus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies fo...

4 months ago - GlobeNewsWire

AUSTIN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today announced ...

4 months ago - GlobeNewsWire

AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies ...

5 months ago - GlobeNewsWire

Investigational drug RNL ™ d eliver s u p to fifteen t imes the a bsorbed d ose of r adiation c ompared to standard e xternal b eam r adiation t herapy

5 months ago - GlobeNewsWire

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today announced ...

5 months ago - GlobeNewsWire

Company Management and Principal Investigator of ReSPECT to Discuss Interim Data

5 months ago - GlobeNewsWire

Data and Safety Monitoring Board evaluated safety data in recommending cohort progression Data and Safety Monitoring Board evaluated safety data in recommending cohort progression

6 months ago - GlobeNewsWire

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

– Receive d FDA O rphan D rug and Fast Track designations for novel glioblastoma radiotherapy –

6 months ago - GlobeNewsWire

AUSTIN, Texas, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has been invited to participate in the Cancer Innovation Summit. The meet...

6 months ago - GlobeNewsWire

AUSTIN, Texas, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced ...

6 months ago - GlobeNewsWire

AUSTIN, Texas, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced the appointment of five leading experts in the fields of neurological surgery and...

7 months ago - GlobeNewsWire

Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™) Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™)

7 months ago - GlobeNewsWire

AUSTIN, Texas, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fas...

7 months ago - GlobeNewsWire

AUSTIN, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that it has been invited to present at the 22nd H. C. Wainwright Annual Glo...

7 months ago - GlobeNewsWire

AUSTIN, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that it has been invited to present at the 9 th Annual Gateway Conferenc...

8 months ago - GlobeNewsWire

Plus Therapeutics (NASDAQ: PSTV) shares are trading higher Tuesday after the company announced the Food and Drug Administration has granted orphan drug designation for Rhenium NanoLiposomes for the trea...

8 months ago - Benzinga

AUSTIN, Texas, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc (Exchange: PSTV) , today announced that it will be presenting at the LD 500 investor conference on Friday, September 4 at 10.20 ...

8 months ago - GlobeNewsWire

Plus Therapeutics, Inc.(PSTV) CEO Marc Hedrick on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

AUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced financial and business results for its Second Quarter Fiscal Year 2020 ended ...

8 months ago - GlobeNewsWire

AUSTIN, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”) today announced that it will report its Second Quarter Fiscal Year 2020 financial results afte...

9 months ago - GlobeNewsWire

AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”) today announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial an...

9 months ago - GlobeNewsWire

AUSTIN, Texas, July 23, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”) today announced that it will be presenting at the YAFO ACCESS CHINA - 2020 Summer Online Partn...

9 months ago - GlobeNewsWire

AUSTIN, Texas, July 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced that the compensation committee of the Company’s board of directors approved an inducement grant...

10 months ago - GlobeNewsWire

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

AUSTIN, Texas, May 14, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced financial and business results for its first quarter fiscal year 2020 ended Ma...

11 months ago - GlobeNewsWire

AUSTIN, Texas, May 11, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”, “Plus”), today announced the closing of its previously announced definitive agreement to licens...

11 months ago - GlobeNewsWire

AUSTIN, Texas, April 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that it is donating personal protective equipment to San Diego’s Scripps Hea...

1 year ago - GlobeNewsWire

AUSTIN, Texas, April 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Dr. Gregory Stein has joined the Company as Senior Vice President of Cl...

1 year ago - GlobeNewsWire

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2019 Results Conference Call March 30, 2020 5:00 PM ET

1 year ago - Seeking Alpha

Plus Therapeutics (NASDAQ: PSTV) shares are trading higher on Monday. The company announced it has entered into an agreement to license multiple rare cancer drug product candidates from NanoTx for an up...

1 year ago - Benzinga

Dr. Robert Lenk and Mr. Howard Clowes Dr. Robert Lenk and Mr. Howard Clowes

1 year ago - GlobeNewsWire

AUSTIN, Texas, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Andrew J. Sims has been appointed as the company’s Chief Financial Offic...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Greg B. Petersen has joined the Company’s Board of Directors to serve as...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”) today issued the following Letter to Shareholders from Dr. Marc Hedrick, President and Chief E...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), today announced that Dr. An van Es-Johansson has joined the Company’s Board of Directors to s...

1 year ago - GlobeNewsWire

Plus Therapeutics, Inc. (PSTV) CEO Dr.

1 year ago - Seeking Alpha

AUSTIN, Texas, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”) today announced that it received a $4.6 million payment from the U.S. Department of Health and...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offe...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced the pricing of an underwritten public offering (the “Offering”) of 3,000,000 un...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”) today announced that it received notice from the U.S. Department of Health and Human Services...

1 year ago - GlobeNewsWire

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
Marc Hedrick
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
PSTV
Full Company Profile

Financial Performance

In 2020, PSTV's revenue was $303,000, a decrease of -95.67% compared to the previous year's $7.00 million. Losses were -$8.24 million, -24.30% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for PSTV stock is "Buy." The 12-month stock price forecast is 6.81, which is an increase of 213.82% from the latest price.

Price Target
$6.81
(213.82% upside)
Analyst Consensus: Buy